UCB is a global biopharmaceutical company dedicated to transforming the lives of people with severe diseases through innovative science and patient-centered solutions. Based in the United States, UCB focuses on key therapeutic areas including neurology, immunology, dermatology, and rare diseases. Their product portfolio features groundbreaking therapies such as BIMZELX, aimed at controlling inflammation in conditions like psoriatic arthritis and axial spondyloarthritis.

At UCB, sustainability is an integral aspect of their business approach, emphasizing the creation of a positive impact on both society and the environment. They prioritize responsible innovation, ensuring that their products are accessible to those who need them while fostering a healthy and safe workplace for their employees. UCB also actively engages with communities through initiatives like the UCB Community Health Fund, which supports vulnerable populations affected by health crises. Through collaboration with patients, partners, and stakeholders, UCB strives to improve health outcomes and contribute to a healthier world for all.